JC-171

• Description:

  JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC50 of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages[1].

• UNSPSC:

  12352005

• Target:

  NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jc-171.html

• Purity:

  98.41

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(NCCC1=CC=C(S(=O)(NO)=O)C=C1)C2=CC(Cl)=CC=C2OC

• Molecular Formula:

  C16H17ClN2O5S

• Molecular Weight:

  384.83

• References & Citations:

  [1]Chunqing Guo, et al. Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2- (4-hydroxysulfamoyl-phenyl) -ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis. ACS Chem Neurosci. 2017 Oct 18;8 (10) :2194-2201.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  NLRP3

• CAS Number:

  [2112809-98-8]